Understand the source comparison
Best Peptides for GERD Natural Treatment: Mechanism Comparison
| Peptide | Primary Mechanism | Tissue Target | Evidence Level | Typical Research Dose | Administration Route | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, nitric oxide modulation | Esophageal mucosa, gastric lining | 30+ preclinical s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Tissue Target | Evidence Level | Typical Research Dose | Administration Route | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, nitric oxide modulation | Esophageal mucosa, gastric lining | 30+ preclinical studies; no human RCTs | 250–500 mcg daily | Oral or subcutaneous | Strongest preclinical evidence for direct mucosal repair; oral bioavailability is an advantage over injectable-only peptides || KPV | NF-κB inhibition, mast cell stabilization | Esophageal epithelium, inflammatory infiltrate | 8 preclinical studies; 1 human IBD trial | 500–1000 mcg daily | Oral or subcutaneous | Best choice for inflammation-driven GERD (eosinophilic esophagitis patterns); weaker evidence for acid-driven injury || Thymosin Beta-4 | Actin regulation, keratinocyte migration | Epithelial barrier | 12 wound-healing studies; no GERD-specific trials | 2–5 mg twice weekly | Subcutaneous only | Secondary peptide for combination protocols; insufficient stand